Cargando…

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting that the development of C16-based lipopeptide...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lan, Qiaoshuai, Chan, Jasper Fuk-Woo, Xu, Wei, Wang, Lijue, Jiao, Fanke, Zhang, Guangxu, Pu, Jing, Zhou, Jie, Xia, Shuai, Lu, Lu, Yuen, Kwok-Yung, Jiang, Shibo, Wang, Qian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8955410/ https://www.ncbi.nlm.nih.gov/pubmed/35336956 http://dx.doi.org/10.3390/v14030549

Ejemplares similares

Peptide-based pan-CoV fusion inhibitors maintain high potency against SARS-CoV-2 Omicron variant
por: Xia, Shuai, et al.
Publicado: (2022)

Lipopeptide-based pan-CoV fusion inhibitors potently inhibit HIV-1 infection
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

SARS-CoV-2 Omicron subvariants exhibit distinct fusogenicity, but similar sensitivity, to pan-CoV fusion inhibitors
por: Xia, Shuai, et al.
Publicado: (2023)

25-Hydroxycholesterol-Conjugated EK1 Peptide with Potent and Broad-Spectrum Inhibitory Activity against SARS-CoV-2, Its Variants of Concern, and Other Human Coronaviruses
por: Lan, Qiaoshuai, et al.
Publicado: (2021)

A pan-sarbecovirus vaccine induces highly potent and durable neutralizing antibody responses in non-human primates against SARS-CoV-2 Omicron variant
por: Liu, Zezhong, et al.
Publicado: (2022)

Structural and functional basis for pan-CoV fusion inhibitors against SARS-CoV-2 and its variants with preclinical evaluation
por: Xia, Shuai, et al.
Publicado: (2021)

Structure-based evidence for the enhanced transmissibility of the dominant SARS-CoV-2 B.1.1.7 variant (Alpha)
por: Xia, Shuai, et al.
Publicado: (2021)

Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages
por: Xia, Shuai, et al.
Publicado: (2022)

Pathogenicity of SARS‐CoV‐2 Omicron
por: Chu, Hin, et al.
Publicado: (2022)

Pathogenicity of SARS-CoV-2 Omicron BA.1.1 in hamsters
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Potential recombination between SARS-CoV-2 and MERS-CoV: calls for the development of Pan-CoV vaccines
por: Wang, Qiao, et al.
Publicado: (2023)

Inefficiency of Sera from Mice Treated with Pseudotyped SARS-CoV to Neutralize 2019-nCoV Infection
por: Liu, Zezhong, et al.
Publicado: (2020)

Altered host protease determinants for SARS-CoV-2 Omicron
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2023)

A bivalent protein targeting glycans and HR1 domain in spike protein potently inhibited infection of SARS-CoV-2 and other human coronaviruses
por: Cai, Yanxing, et al.
Publicado: (2021)

Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
por: Xia, Shuai, et al.
Publicado: (2020)

A trifunctional peptide broadly inhibits SARS-CoV-2 Delta and Omicron variants in hamsters
por: Zhao, Hanjun, et al.
Publicado: (2022)

Potent MERS-CoV Fusion Inhibitory Peptides Identified from HR2 Domain in Spike Protein of Bat Coronavirus HKU4
por: Xia, Shuai, et al.
Publicado: (2019)

Fusion-inhibition peptide broadly inhibits influenza virus and SARS-CoV-2, including Delta and Omicron variants
por: Zhao, Hanjun, et al.
Publicado: (2022)

Virological features and pathogenicity of SARS-CoV-2 Omicron BA.2
por: Chan, Jasper Fuk-Woo, et al.
Publicado: (2022)

Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with Omicron breakthrough infection
por: Guo, Yu, et al.
Publicado: (2023)

Peptidic defective interfering gene nanoparticles against Omicron, Delta SARS-CoV-2 variants and influenza A virus in vivo
por: Zhao, Hanjun, et al.
Publicado: (2022)

A pan-sarbecovirus vaccine based on RBD of SARS-CoV-2 original strain elicits potent neutralizing antibodies against XBB in non-human primates
por: Liu, Zezhong, et al.
Publicado: (2023)

A bipotential organoid model of respiratory epithelium recapitulates high infectivity of SARS-CoV-2 Omicron variant
por: Chiu, Man Chun, et al.
Publicado: (2022)

Antibody evasion properties of SARS-CoV-2 Omicron sublineages
por: Iketani, Sho, et al.
Publicado: (2022)

SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread
por: Wang, Xinling, et al.
Publicado: (2023)

A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants
por: Lam, Joy-Yan, et al.
Publicado: (2022)

A broadly neutralizing antibody protects Syrian hamsters against SARS-CoV-2 Omicron challenge
por: Zhou, Biao, et al.
Publicado: (2022)

Renaming the SARS‐CoV‐2 Omicron sublineages as SARS‐CoV‐3 is contrary to nomenclature standards based on evolutionary and serological evidence
por: Qi, Zhongtian, et al.
Publicado: (2022)

Developing pan-β-coronavirus vaccines against emerging SARS-CoV-2 variants of concern
por: Su, Shan, et al.
Publicado: (2022)

Is Omicron the last SARS-CoV-2 Variant of Concern?
por: Rahimi, Farid, et al.
Publicado: (2022)

Characteristic analysis of Omicron‐included SARS‐CoV‐2 variants of concern
por: Yang, Hao, et al.
Publicado: (2022)

A new class of α-ketoamide derivatives with potent anticancer and anti-SARS-CoV-2 activities
por: Wang, Juan, et al.
Publicado: (2021)

SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
por: Yuen, Chun-Kit, et al.
Publicado: (2020)

Spike mutations contributing to the altered entry preference of SARS-CoV-2 omicron BA.1 and BA.2
por: Hu, Bingjie, et al.
Publicado: (2022)

Potent Neutralization of Omicron and other SARS-CoV-2 Variants of Concern by Biparatopic Human VH Domains
por: Chen, Chuan, et al.
Publicado: (2022)

Clinical Performance of the Luminex NxTAG CoV Extended Panel for SARS-CoV-2 Detection in Nasopharyngeal Specimens from COVID-19 Patients in Hong Kong
por: Chen, Jonathan Hon-Kwan, et al.
Publicado: (2020)

Enhanced replication of SARS-CoV-2 Omicron BA.2 in human forebrain and midbrain organoids
por: Hou, Yuxin, et al.
Publicado: (2022)

Broad-spectrum humanized monoclonal neutralizing antibody against SARS-CoV-2 variants, including the Omicron variant
por: Wen, Kun, et al.
Publicado: (2023)

Omicron: A SARS‐CoV‐2 variant of real concern
por: Gattinger, Pia, et al.
Publicado: (2022)

SARS‐CoV‐2 Omicron variant: Characteristics and prevention
por: He, Xuemei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bje7sspcr06njvsk3vubfl3ts8